The study, published in Clinical Cancer Bulletin, drew on one of the largest single-center myeloma cohorts in China, spanning patients diagnosed between January 2010 and April 2021. Of the 812 patients enrolled, 703 did not undergo autologous stem cell transplantation and were randomly split into a training set of 527 and a validation set of 176, while 109 transplant recipients formed a separate group. All patients received guideline-consistent first-line therapy built around proteasome inhibitors, immunomodulators, or both, ensuring that differences in outcome could be attributed to disease biology rather than wildly different treatments.

What sets the study apart is its breadth. Rather than focusing narrowly on the cytogenetic abnormalities that dominate contemporary myeloma research, the investigators collected everything from hemoglobin and platelet counts to complement proteins, interleukin levels, anion gap, and the patient’s overall functional status as measured by the Eastern Cooperative Oncology Group (ECOG) scale. Missing data, which affected fewer than 15 percent of values for any parameter, were handled with multiple imputation by chained equations, a statistical technique that generates several plausible completed datasets and pools the results to avoid bias.

In the first pass, univariate Cox regression analysis of the training set identified 29 parameters with measurable prognostic value when treated as continuous variables. When the researchers converted those variables into clinically practical categories, using thresholds such as the International Myeloma Working Group criteria for anemia, renal insufficiency, and hypercalcemia, 25 parameters retained their predictive power. Notably, some familiar markers lost their luster in this transformation: age, M protein quantification, and alkaline phosphatase no longer distinguished survivors from non-survivors once dichotomized, while urea nitrogen emerged as newly informative.

The decisive filtering came with multivariate Cox regression, which tests whether each parameter adds predictive value independently of all the others. Ten factors survived: ECOG performance score, the presence of extramedullary lesions, platelet count, reticulocyte count, anion gap, hypercalcemia, complement C3, beta-2 microglobulin, high-risk cytogenetics, and interleukin-2 receptor levels. Some of these, such as beta-2 microglobulin and cytogenetic abnormalities, are already embedded in mainstream staging systems. Others, including the anion gap, a routine electrolyte-derived measure, and the reticulocyte count, a marker of bone marrow’s regenerative capacity, have been almost entirely overlooked in myeloma prognostication.

Several of these findings challenge conventional wisdom. Albumin, a cornerstone of the International Staging System for two decades, showed prognostic value in univariate analysis but failed to hold up in the multivariate model. The proportion of plasma cells in the bone marrow, often assumed to reflect tumor burden, likewise did not independently predict outcome, which the authors attribute to the disease’s profound internal heterogeneity: how the tumor behaves matters more than how large it is. Meanwhile, 1q21 gain or amplification, an abnormality given weight in the newest R2-ISS staging revision, did not reach statistical significance in this cohort.

The researchers also benchmarked the four widely used staging systems, Durie-Salmon, ISS, R-ISS, and R2-ISS, against real-world outcomes using time-dependent receiver operating characteristic curves. The results were sobering. The best performer, R2-ISS, achieved areas under the curve of roughly 0.68 to 0.72 for one-, three-, and five-year overall survival, while the Durie-Salmon system hovered near 0.52 to 0.54, barely better than a coin flip. In a disease where treatment intensity decisions hinge on risk category, that margin of error carries real clinical consequences.

From the ten surviving parameters, the team constructed the Zhongshan Risk Score, a weighted sum in which each factor contributes according to its Cox regression coefficient, with beta-2 microglobulin, platelet count, and hypercalcemia carrying the heaviest weights. Using a cut-off of 2.02, patients in the training set split cleanly into high- and low-risk groups with dramatically different overall and progression-free survival, both differences highly significant. The score held up in the validation set and, importantly, also stratified the 109 transplant patients, suggesting it applies across treatment modalities. Its accuracy was striking: area under the curve values of 0.81, 0.81, and 0.83 for one-, three-, and five-year survival, comfortably exceeding every existing staging system. A companion nomogram translates the score into estimated one-, three-, and five-year survival probabilities for individual patients.

The biology behind the novel markers remains speculative but tantalizing. Complement C3, a central protein of the innate immune system, can activate macrophages and drive complement-dependent cytotoxicity, potentially mirroring the body’s anti-tumor response. Interleukin-2 receptor, by contrast, acts as a negative immunomodulator, and elevated levels have previously been linked to treatment resistance in myeloma. The anion gap’s role is murkier, possibly reflecting metabolic derangement or renal impairment, while reticulocyte and platelet counts appear to capture the residual health of the bone marrow’s normal hematopoietic machinery, a dimension that hemoglobin alone fails to convey.

The authors are candid about limitations. The study is retrospective and single-center, raising questions about generalizability across ethnic groups and health systems, and emerging biomarkers such as circulating tumor DNA were not available for analysis. The transplant subgroup was small, warranting caution. Still, the implications are considerable: a cheap, widely accessible panel of routine blood tests and clinical assessments could sharpen risk stratification beyond what expensive cytogenetic panels achieve alone, potentially guiding which patients warrant early escalation to monoclonal antibodies or CAR T-cell therapy, and which can be spared overtreatment. External validation in multicenter prospective cohorts will determine whether the Zhongshan Risk Score earns a place beside, or above, the staging systems it just outperformed.

Subject of Research: Prognostic clinical parameters and risk stratification in multiple myeloma

Article Title: Comprehensive evaluation of clinical prognostic parameters in a real-world cohort of 812 patients with multiple myeloma

Article References: Wang, Y., Lan, T., Zhou, C., Xu, T., & Liu, P. (2025). Comprehensive evaluation of clinical prognostic parameters in a real-world cohort of 812 patients with multiple myeloma. Clinical Cancer Bulletin, 4(1), Article 4. https://doi.org/10.1007/s44272-025-00031-5

Image Credits: AI Generated

DOI: 10.1007/s44272-025-00031-5

Keywords: multiple myeloma, prognosis, risk score, biomarkers, staging systems, beta-2 microglobulin, cytogenetics, ECOG score, complement C3, interleukin-2 receptor, real-world cohort, hematology

The question at the heart of the editorial is deceptively simple: why would medical graduates avoid a specialty at the frontier of precision medicine? The first answer is psychological weight. Practicing hematology carries a significant emotional burden and demands considerable time, placing physicians at elevated risk of burnout, particularly female and younger doctors. A survey by the European Hematology Association found that early-career hematologists face workload imbalance, uncertainty, and insufficient structural support, all of which compound their emotional strain. The second answer is structural: in recent decades, a large share of patients with hematological malignancies have shifted from time-limited treatment courses to continuous therapy. Chronic myeloid leukemia, myeloma, and relapsed lymphomas are increasingly managed as long-term conditions, which has driven up demand for hospital admissions, outpatient visits, and monitoring resources. More effective drugs have paradoxically made the specialty more labor-intensive, because surviving patients keep returning to the same over-stretched units.

A third force is generational and digital. The widespread use of social media and online platforms has made younger graduates acutely aware of what hematology training actually looks like from the inside. Prospective fellows can now read candid accounts from current trainees about night shifts, emotional exhaustion, and administrative drudgery before they ever submit an application. Ciccone argues that this transparency should not be mistaken for weak motivation. Choosing a specialty with better work-life balance, she writes, reflects an awareness that personal and professional life are equally significant, not a lack of commitment to patients. The preference pattern suggests that graduates are making informed calculations about sustainability, and hematology currently scores poorly in those calculations compared with specialties perceived as offering more protected personal time.

The technical evolution of the field itself has created a training paradox. Hematology has become extraordinarily complex, requiring highly specialized skills and continuous updating as targeted agents, bispecific antibodies, and cell therapies proliferate. Some fellowship programs have responded by developing pathways in which trainees focus on only one group of hematological diseases, a model sometimes described as one fellowship, one disease. In health systems where graduates will later work within narrow, highly specialized teams, this model is efficient. But in much of Italy it is not. At smaller hematology centers, a single physician must maintain a broad skill set, spanning the diagnosis of myeloproliferative syndromes and the acute management of leukemia. Trainees educated exclusively on highly selected patient populations may therefore experience a crisis of self-confidence when recruited to spoke centers, where the full spectrum of hematological care lands on their desks.

Academic aspiration adds another layer of friction. Hematology in Italy is practiced primarily in public institutions, large hospitals, and a handful of affiliated outpatient clinics, settings that offer limited opportunities to build a career combining research or education with clinical training. Most Italian hematologists, including trainees, can dedicate only scraps of time to research and in-depth study, often at the expense of free time or family life, and many must seek research opportunities outside their clinical institutions, sometimes in larger academic centers abroad. Layered on top of this are workplace stressors familiar across Italian medicine: inadequate staffing, administrative burden, and the management pressures of the National Health Service. There is also growing pressure to use expensive medications judiciously, in a system that has historically provided such drugs to patients without direct charge, while patients reasonably expect unrestricted access to treatments that could cure them. Managing that tension is itself a source of burnout.

Ciccone is careful to note that not every driver is unique to hematology or to Italy. The feminization of the medical workforce, rising attention to work-life balance, and expanding administrative load are shared across specialties and health systems. What does appear specific to hematology is the combination of rapid therapeutic innovation, the emotional intensity of caring for patients with life-threatening or incurable diseases, and the narrowing one-disease training model. That distinction matters for policy, because it means generic workforce remedies may not suffice. If the specialty’s particular features are repelling candidates, then the response must address the emotional architecture of blood-disease care and the design of training, not merely pay or vacation time.

The downstream consequences for patients are concrete and measurable. A shortage of trained hematologists would translate into longer waiting times for diagnosis and treatment initiation, while the workload of the remaining workforce would rise disproportionately, generating a vicious cycle in which burnout risk climbs further. Care complexity raises the stakes: the last two decades brought targeted therapies, CAR-T cell treatments, bispecific antibodies, and increasingly individualized transplant strategies, and delivering these safely requires experienced physicians at every step of the patient journey. A workforce gap therefore threatens the very continuity of specialized care that has made many hematological malignancies curable or chronically manageable. Smaller and peripheral hospitals would be hit hardest, since a limited number of physicians there must cover the entire spectrum of hematological care, leaving patients outside major urban areas facing inequitable access to timely diagnosis, clinical trial enrollment, and advanced treatment.

The hub-and-spoke organization of Italian hematology only functions when both ends are adequately staffed. When spoke centers lack trained hematologists, patients funnel toward hub centers, producing overcrowding and reduced capacity for individualized care. Italy’s geography makes such migration easy, but it imposes real costs: travel expenses for gasoline or public transport fall on patients, translating into worse quality of life and widening inequalities in access, a burden documented in studies of relapsed and refractory myeloma. Beyond the present system, the shortage threatens the future itself, jeopardizing the continuity of clinical research, the education of the next generation of specialists, and Italy’s capacity to remain at the forefront of a field advancing at unprecedented pace. Patients deserve not only existing treatments but also access to trials and innovations still in development, which requires a vibrant, well-staffed, motivated workforce.

The proposed remedies span individual, institutional, and system levels. Ciccone calls for structural changes that guarantee better work-life balance for all hematology professionals, including psychological support during training, flexible schedules, and supportive services such as workplace childcare, a measure aimed squarely at a workforce that is now majority female and faces disproportionate domestic responsibilities, communication demands, and workplace inequities. Mentorship programs with real accountability could reduce time lost to redundant tasks and self-directed learning while promoting academic research during clinical training. Institutions should also teach end-of-life care and facilitate honest discussions about disease trajectory and quality of life, easing the burden on trainees, patients, and the system alike. Drawing on her experience at two academic centers, Ciccone observes that trainees are often uncomfortable with clinical uncertainty, and she invokes Nassim Nicholas Taleb’s critique of physicians who assume medicine is fully predictable, arguing that learning to voice doubt and failure honestly could reduce the sense of inadequacy among young doctors and improve the patient experience.

At the system level, the editorial proposes telemedicine networks that would let specialized hub centers provide teleconsultation to clinicians at spoke facilities, aligning better with the one-disease training model while preventing overcrowding of referral centers. Artificial intelligence tools, Ciccone suggests, may eventually relieve physicians of administrative burdens without replacing the irreplaceable clinical role of the hematologist. She also flags unresolved financial questions, including gender pay gaps and differences between public and private practice, that likely shape career choices and deserve comparative study across specialties and countries. Perhaps the most sobering observation is international: the declining appeal of hematology appears even in high-income countries offering higher salaries and stronger family support, suggesting that care complexity and burnout risk weigh more heavily on career decisions than compensation alone. The crisis, in other words, is not an Italian anomaly but a warning to hematology worldwide, and the specialty’s ability to reinvent its training, its workload, and its honesty about uncertainty may determine whether the next generation of blood-disease experts exists at all.

Subject of Research: Declining recruitment into hematology fellowships in Italy and its impact on patient care

Article Title: Hematology at a Crossroads: Why Young Physicians in Italy Are Turning Away

Article References: Hematology at a Crossroads: Why Young Physicians in Italy Are Turning Away. (n.d.). https://doi.org/10.1007/s12325-026-03782-2

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03782-2

Keywords: hematology, Italy, fellowship shortage, burnout, medical training, workforce, CAR-T, healthcare inequality, mentorship, telemedicine, hematological malignancies, work-life balance

The problem begins with a formulation that has served statistics well for more than four decades. Cumulative-link ordinal models, introduced by McCullagh in 1980, classify ordered categories by placing a latent score on an axis and slicing that axis with learned thresholds. The probability of landing in any interior category is computed as the difference of two sigmoid functions evaluated at adjacent thresholds. This elegant construction underpins the proportional odds model, the CORAL ordinal regression framework, and softplus-reparameterized variants used throughout deep learning, from age estimation to histopathological grading. But the researchers point out an elementary consequence that is rarely confronted in the deep learning era: the maximum probability achievable for any interior stage is bounded by the gap between its two neighboring thresholds. The bound is tight and has a closed form, Pmax(g) = 2σ(g/2) − 1, and it applies to every model built on this sigmoid-difference formulation.

The numbers make the danger vivid. When the threshold gap equals 1.0, an interior category can never exceed a probability of 0.245, meaning the argmax decision rule will almost never select it, no matter how powerful the network, how long the training, or how abundant the data. At a gap of 2.0 the ceiling rises to 0.462, and at roughly 3.0 it reaches 0.635. The ceiling is a property of the sigmoid parameterization itself, and the authors note that it was already known in the psychometrics literature on graded response models, where Samejima studied the same category response function in 1969. What classical item-response theory never addressed, however, is what happens when such parameters are estimated by stochastic gradient descent on severely imbalanced image batches rather than by maximum likelihood on balanced matrices.

That imbalance is exactly where the failure mode becomes acute. In clinical datasets of peripheral blood cells, mature segmented neutrophils outnumber early-stage myelocytes by ratios exceeding 100 to 1. The dominant endpoint class sits far above all interior thresholds on the latent axis, so it contributes essentially no gradient at the interior boundaries. Meanwhile, the rare interior samples that would push those thresholds apart are too few, and too poorly positioned early in training, to supply the restoring force. The result is a self-reinforcing feedback loop: narrow gaps keep interior stages hard to place, and misplaced interior samples keep the gaps narrow. The researchers derive the threshold gradients explicitly and show that a correctly positioned interior sample exerts a widening force that grows monotonically as the gap shrinks and diverges as the gap approaches zero, a restoring mechanism that can rescue a collapsing configuration once features become separable.

To test these predictions, the team built HemoCline, a convolutional network of just 532,131 parameters whose backbone is assembled from mobile inverted bottleneck blocks, the same efficient building blocks behind the MobileNet family. On top of this shared backbone sits a hierarchical classification head that routes cells through biologically motivated branches, mirroring the taxonomy of granulocytes, agranulocytes, red cell lineage, and platelets, and then classifies granulocyte maturation stages through a cumulative-link head with learnable, strictly ordered boundaries enforced by softplus reparameterization. The four modeled stages follow the well-characterized neutrophilic maturation sequence from myelocyte to metamyelocyte to band neutrophil to segmented neutrophil, with each transition marked by progressive nuclear condensation and lobulation that human annotators discretize into stages.

The experimental validation ran on two independent public datasets: the KU-Optofil dataset from Turkey, containing 31,489 images across 13 classes with a striking 167 to 1 imbalance between its largest and smallest maturation classes, and the Barcelona PBC dataset from Spain with 17,092 images across 8 classes. Trained entirely from scratch without ImageNet pretraining, HemoCline reached 98.86 percent macro-F1 on Barcelona and 93.36 percent accuracy on KU-Optofil’s harder 13-class task. Under an identical from-scratch recipe, it matched MobileNetV3-Small on accuracy with 2.9 times fewer parameters while exceeding it on macro-F1, maturation-chain F1, calibration, and seed-to-seed stability. Against the best-performing pretrained model of the original KU-Optofil benchmark, DenseNet-121 at 13 times the parameter count, HemoCline sits 1.9 percentage points lower on accuracy, a gap the authors attribute honestly to capacity rather than claiming parity.

Perhaps the most scientifically interesting results are the ones the authors report against their own expectations. The study pre-registered four hypotheses, and two were falsified. The Maturation Coordinate, the scalar output of the ordinal head, was predicted to form a smooth continuum correlating strongly with true stage; instead it converged to four separated clusters, with a Spearman correlation of just 0.30 against a pre-specified threshold of 0.75. Yet the clusters discriminate powerfully between adjacent stages, with Cliff’s delta reaching nearly perfect separation for the metamyelocyte-to-band transition. The model, in other words, learns to distinguish stages without interpolating between them. The second falsification concerned cross-laboratory transfer: adjusting only the learned thresholds on data from a new laboratory recovered 76.5 percent macro-F1, far short of the 91 percent achieved by retraining the full classification head, because branch and sub-head probabilities shift between laboratories just as the maturation boundary does.

The threshold dynamics themselves behaved as the gradient analysis predicted, but with a twist. Starting from a deliberately narrow initialization with a gap of 1.0, where the ceiling analysis predicts near-zero interior recall, the optimizer self-widened the gaps to an average of about 2.0 within 40 epochs, confirming the restoring-force mechanism. But the gap-floor regularizer the team derived from the closed-form minimum gap formula turned out to be inactive at the working initialization, where gaps already sat above the floor, and it failed to rescue a shortened training schedule. An ablation against CORN, an ordinal method that avoids the ceiling by construction, was statistically indistinguishable from the cumulative-link head across five seeds. The authors conclude that the ceiling is real and observable at narrow initializations, but that the correct response is a wider initialization and monitoring of gap trajectories rather than an added loss term, and they offer the closed-form minimum gap as a diagnostic grounded in the stage count rather than a grid search.

The study also distinguishes carefully between the two head configurations and what each is for. On aggregate metrics the flat, non-ordinal head matches or slightly beats the ordinal one, and it wins on agranulocyte separation, distinguishing lymphocytes from reactive lymphocytes and blasts more reliably. The ordinal head earns its place on the sub-task it was designed around: maturation-stage resolution improves, with quadratic weighted kappa rising from 0.815 to 0.877, and the hardest class, band neutrophil, shows three times lower seed-to-seed variability. The choice between them, the authors argue, is a choice about which errors a deployment can absorb. All configurations passed the team’s multi-seed deployment-readiness protocol, which trains five copies differing only in random seed and requires both low coefficient of variation and no seed below pre-committed performance floors.

The practical implications reach beyond hematology. The interior-stage bound applies to any model computing category probabilities as differences of sigmoid threshold terms, and the authors suggest that tasks with more ordinal stages, where the same latent axis must accommodate more boundaries and tighter gaps, are where the collapse phenomenon should matter most. For point-of-care devices operating under tight memory and latency budgets, a 532 K-parameter network that runs in under 2 milliseconds on CPU offers a credible alternative to the massive pretrained backbones that dominate the literature. The authors are candid about limitations: myelocyte classification remains poor for both configurations with only 68 training examples, the transfer analysis spans just two laboratories, and clinical deployment would require prospective validation and regulatory clearance. But as a demonstration that a small, biologically structured model can approach the accuracy of giants while exposing a hidden mathematical trap in the process, the work marks a compelling step toward AI that understands not just what a cell is, but where it sits along the road of its own maturation.

Subject of Research: Threshold gap dynamics in cumulative-link ordinal models for imbalanced blood cell maturation classification

Article Title: HemoCline: Threshold gap dynamics in cumulative-link ordinal models for imbalanced blood cell maturation

Article References: Daga, M., Bommineni, K. R., & Ramu, S. P. (2026). HemoCline: Threshold gap dynamics in cumulative-link ordinal models for imbalanced blood cell maturation. Machine Learning with Applications, 26, Article 101031. https://doi.org/10.1016/j.mlwa.2026.101031

Image Credits: AI Generated

DOI: 10.1016/j.mlwa.2026.101031

Keywords: ordinal regression, cumulative-link models, blood cell classification, class imbalance, neutrophil maturation, HemoCline, lightweight neural networks, hematology, deep learning, threshold dynamics, medical imaging, machine learning

The research, led by Minglu Li and colleagues at the Department of Hematology of Aerospace Center Hospital in Beijing, set out to build what statisticians call a nomogram — a visual scoring instrument that converts a handful of patient characteristics into a personalized probability estimate. What makes this nomogram distinctive is its statistical engine: rather than treating death from any cause as a single uniform outcome, the team used a competing-risk framework that explicitly accounts for the fact that a patient who relapses and dies of leukemia is no longer at risk of dying from transplant complications. In survival analysis, ignoring such competing events can badly distort risk estimates, inflating apparent mortality rates and muddying clinical decision-making. The Fine-Gray model, the framework the researchers adopted, was developed precisely to handle this subtlety, modeling the cumulative incidence of the event of interest while treating relapse as the competing event.

The study population consisted of 587 patients with high-risk or refractory acute leukemia who underwent their first allogeneic transplant between January 2015 and December 2021 at the single center. To test the model honestly, the team randomly split the cohort into a training set of 411 patients, used to build the model, and a validation set of 176 patients, held back to see how the model performed on data it had never seen. This kind of internal validation is a critical safeguard against overfitting — the statistical sin of building a model that memorizes the quirks of one dataset rather than capturing genuine biological patterns that generalize to new patients.

Selecting which variables to include was itself a methodical process. The researchers turned to least absolute shrinkage and selection operator regression, better known as LASSO, a technique that shrinks the coefficients of weak predictors toward zero and effectively eliminates them, leaving behind only the most informative variables. To ensure the selection was stable rather than a fluke of the particular data, they employed ten-fold cross-validation, repeatedly partitioning the training data so that the variable selection process was tested across many different subsets. Out of this rigorous filtering emerged six predictors of non-relapse mortality: patient age, disease status before transplantation (whether the leukemia was in complete remission or not), the Hematopoietic Cell Transplantation-specific Comorbidity Index score, the time to white blood cell engraftment, the time to platelet engraftment, and the grade of acute graft-versus-host disease.

Each of these predictors tells a clinically meaningful story. Age and comorbidities reflect the body’s baseline resilience going into the procedure — an older patient with significant organ dysfunction simply has less physiological reserve to withstand the assault of conditioning chemotherapy, immune suppression, and potential infections. Pre-transplant disease status matters because patients transplanted in complete remission generally fare better than those transplanted with active, refractory disease. The engraftment timings are particularly interesting because they are early post-transplant events: if the donor’s stem cells take longer than 21 days to produce white blood cells, or longer than 14 days to produce platelets, that sluggish recovery signals a fragile marrow environment associated with higher risk. And acute graft-versus-host disease — the notorious complication in which donor immune cells attack the recipient’s tissues — remains one of the most feared drivers of transplant-related death, so its grade from II to IV carries substantial weight in the model.

The performance numbers are where the tool earns its keep. In the training cohort, the time-dependent area under the receiver operating characteristic curve — a standard measure of how well a model separates those who experience the event from those who do not — reached 0.786 at one year, 0.764 at two years, and 0.746 at three years. In the validation cohort, the model actually performed slightly better, with AUCs of 0.818, 0.799, and 0.806 at the same time points. Values in this range indicate useful, though not perfect, discrimination. The concordance index, a related measure of predictive accuracy for survival data, came in at 0.715 after bootstrap correction in the training set and 0.767 in the validation set, where the 95 percent confidence interval spanned 0.703 to 0.831.

Discrimination alone is not enough, however; a model must also be calibrated, meaning its predicted probabilities should match observed reality. A model that tells every patient they have a 30 percent risk when only 10 percent actually die is discriminating poorly or calibrating poorly, and clinicians acting on such numbers could make harmful decisions. The team assessed calibration using optimism-corrected calibration slopes derived from 200 bootstrap resamples, obtaining values of 0.94, 0.92, and 0.97 at one, two, and three years in the training cohort — figures close to the ideal value of 1.0. In the validation cohort, the slopes of 1.30, 1.14, and 1.16 suggested the model was, if anything, slightly conservative in that patient group, a direction of error that is generally less dangerous than overconfidence.

Perhaps the most practically important result came from the head-to-head comparison with the HCT-CI, the comorbidity index that has long served as a standard pre-transplant risk assessment tool. The new nomogram significantly outperformed it, with a C-index difference of 0.114 (P = 0.020) in the training cohort and 0.191 (P = 0.008) in the validation cohort. The advantage makes intuitive sense: the HCT-CI captures only the patient’s condition before the transplant, whereas the nomogram folds in early post-transplant events like engraftment speed and graft-versus-host disease, which carry fresh, dynamic information about how the transplant is actually unfolding. Decision curve analysis reinforced the point, showing that across clinically relevant threshold probabilities from 5 to 50 percent, the nomogram delivered positive net benefit and consistently beat both the treat-all and treat-none default strategies — meaning that clinicians using the tool to guide decisions would, on average, make better calls than following blanket policies.

The study’s limitations are worth keeping in view. It was a single-center, retrospective analysis, and all 587 patients were treated at one institution in Beijing, so the model’s generalizability to other populations, donor types, and conditioning regimens remains to be demonstrated. External validation on independent cohorts at different centers is the natural next step, and the authors themselves frame the tool as internally validated rather than externally proven. Still, the work represents a meaningful advance in a field where risk prediction has often relied on static, pre-transplant snapshots. By integrating baseline characteristics with the early dynamics of recovery, the nomogram gives clinicians a living risk estimate that can be computed in the crucial weeks after transplantation — precisely the window when interventions such as intensified monitoring, prophylactic treatments, or early escalation of care might tip the balance for the patients who need it most. For the growing population of high-risk and refractory leukemia patients whose only curative option is an allogeneic transplant, turning the black box of non-relapse mortality into a quantifiable, actionable number could ultimately mean the difference between anticipation and reaction.

Subject of Research: A competing-risk nomogram for predicting non-relapse mortality after allogeneic hematopoietic stem cell transplantation in high-risk or refractory acute leukemia

Article Title: Development and internal validation of a competing-risk nomogram for predicting non-relapse mortality after allogeneic hematopoietic stem cell transplantation in patients with high-risk or refractory acute leukemia

Article References: Li, M., Zhang, W., Zhang, S., Fei, X., Zhao, J., Luo, R., & Wang, J. (2026). Development and internal validation of a competing-risk nomogram for predicting non-relapse mortality after allogeneic hematopoietic stem cell transplantation in patients with high-risk or refractory acute leukemia. Annals of Hematology. https://doi.org/10.1007/s00277-026-07294-5

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07294-5

Keywords: non-relapse mortality, allogeneic hematopoietic stem cell transplantation, acute leukemia, nomogram, competing-risk model, Fine-Gray model, LASSO regression, HCT-CI, graft-versus-host disease, engraftment, risk prediction, hematology

The rationale behind the study is straightforward. In healthy individuals, the immature platelet fraction typically accounts for only a small percentage of all platelets, and it rises when the marrow is under pressure to replenish circulating platelets, for example after chemotherapy or in immune thrombocytopenia. In myelodysplastic syndromes, however, the marrow is intrinsically dysfunctional, and the relationship between platelet production and clinical outcome is far less predictable. If a high IPF reflects compensatory but ineffective platelet output, or if it signals biologically more aggressive disease, then the measurement might help clinicians identify patients at higher risk of leukemic transformation or death. Conversely, if the IPF adds nothing beyond established scoring systems, its clinical use would need to be reconsidered.

To address these questions, the researchers designed a two-part investigation. The retrospective arm drew on 364 patients with myelodysplastic syndromes whose baseline IPF values and clinical courses were available from hospital records. The prospective arm enrolled 46 patients under a registered observational protocol, identified as UMIN000057807, in whom the investigators followed outcomes forward in time with standardized assessments. The primary endpoint in both analyses was leukemia-free survival, a composite measure defined as the time until either transformation to acute myeloid leukemia or death from any cause. Secondary endpoints included overall survival and, among patients treated with the hypomethylating agent azacitidine, the rate of hematological improvement.

The retrospective results provided the first hint that the IPF might carry prognostic weight. Using a cutoff of 6.8 percent, the researchers divided the 364 patients into low and high IPF groups and found that 50 leukemia-free survival events occurred during follow-up. Patients whose baseline IPF exceeded 6.8 percent experienced significantly shorter leukemia-free survival and shorter overall survival in unadjusted analyses, with log-rank p values of 0.033 and 0.022 respectively. In a univariable model, a high IPF was associated with a hazard ratio of 1.79 for leukemia-free survival, meaning a roughly 79 percent increase in the risk of leukemic transformation or death, with a 95 percent confidence interval spanning 1.02 to 3.16.

Prognostic research, however, demands caution before celebrating any single variable, and the adjusted analyses told a more nuanced story. When the investigators controlled for age, platelet count, and the Revised International Prognostic Scoring System, a widely used risk stratification tool in myelodysplastic syndromes, the association retained a similar magnitude but lost statistical significance. The adjusted hazard ratio for leukemia-free survival was 2.02, with a 95 percent confidence interval of 0.98 to 4.18 and a p value of 0.057, sitting just at the threshold of conventional significance. The point estimate actually grew larger after adjustment, suggesting the IPF may capture information beyond standard scores, but the wide confidence interval reflects the limited number of events and leaves the conclusion uncertain. The discriminatory performance of the continuous IPF was likewise modest, with a two-year time-dependent area under the curve of 0.638 and a 95 percent confidence interval of 0.561 to 0.715, well short of the near-perfect separation clinicians would want from a standalone biomarker.

The study also probed the biological meaning of the IPF by comparing it with direct examination of the bone marrow. The continuous IPF value showed a moderate correlation with the bone marrow megakaryocyte count, quantified by a Spearman’s rank correlation coefficient of 0.50 with a p value below 0.001. Interestingly, however, the median megakaryocyte counts were identical across the high and low IPF groups, indicating that the correlation, while statistically robust, did not translate into a simple categorical distinction. This pattern suggests that the IPF reflects not merely how many megakaryocytes populate the marrow but how productively those cells release platelets, a functional dimension that conventional morphology may miss in dysplastic marrow.

The prospective cohort was intended to test these retrospective signals under more controlled conditions, and here the picture shifted. Among the 46 prospectively enrolled patients, overall survival and leukemia-free survival did not differ between those with an IPF at or below 6.8 percent and those above the threshold, with log-rank p values of 0.929 and 0.402 respectively. The explanation lies partly in the numbers: only three deaths and four leukemia-free survival events occurred in this small cohort, far too few to detect anything but a dramatic effect. Exploratory prospective studies of this size are inherently underpowered, and the absence of a difference should be read as inconclusive rather than as evidence that the IPF is prognostically irrelevant.

The azacitidine analysis added a therapeutic dimension to the investigation. Azacitidine, a hypomethylating agent, is a mainstay of treatment for higher-risk myelodysplastic syndromes, yet responses vary considerably between patients, and clinicians lack reliable predictors of who will benefit. Among response-evaluable patients treated with azacitidine, hematological improvement occurred in 4 of 14 patients, or 28.6 percent, in the high IPF group, compared with 5 of 8 patients, or 62.5 percent, in the low IPF group. The difference is striking in relative terms but did not reach statistical significance, with a p value of 0.187, and the tiny denominators make any interpretation speculative. Still, the direction of the effect raises the possibility that a high IPF, perhaps signaling more severely disordered thrombopoiesis, could be associated with reduced responsiveness to azacitidine, a hypothesis that only adequately powered trials can confirm or refute.

The authors are careful to frame the IPF as an investigational biomarker rather than a validated clinical tool, and their caution is warranted. The measurement itself is attractive: it is generated automatically by modern hematology analyzers using fluorescent dyes or equivalent technologies that stain RNA-rich reticulated platelets, requires no additional blood draw, and delivers results within the routine complete blood count workflow. Yet the present study demonstrates the classic challenges of biomarker research in rare malignancies. The retrospective signal was genuine but weakened after adjustment for established prognostic factors, the prospective cohort was too small to confirm or refute it, and the discriminatory capacity of the marker was modest at best. The investigators explicitly call for validation in adequately powered multicenter cohorts, which would allow event numbers sufficient for stable adjusted estimates and subgroup analyses across disease risk categories.

For patients and clinicians, the takeaway is one of tempered interest rather than immediate practice change. The immature platelet fraction is not yet ready to join the Revised International Prognostic Scoring System or molecular risk panels in guiding treatment intensity or transplant decisions. What the study does establish is a credible biological and statistical foundation for continued investigation: a plausible mechanism linking platelet turnover to disease behavior, a reproducible retrospective association, and a prospectively collected dataset that can inform the design of larger studies. As flow cytometry-derived and analyzer-derived markers of hematopoietic stress accumulate, the IPF may ultimately find its place alongside other measures in a composite prognostic model. Until such validation arrives, the 6.8 percent threshold remains a research cutoff, not a clinical decision point, and patients with myelodysplastic syndromes will continue to be risk-stratified by the established tools that decades of evidence have validated.

Subject of Research: Prognostic value of the immature platelet fraction in myelodysplastic syndromes

Article Title: The immature platelet fraction in myelodysplastic syndromes: retrospective associations and exploratory prospective cohort assessment

Article References: Yamasaki, S., Hashiguchi, M., Yoshida-Sakai, N., Jojima, H., Osaki, K., Okamura, T., & Imamura, Y. (2026). The immature platelet fraction in myelodysplastic syndromes: retrospective associations and exploratory prospective cohort assessment. Annals of Hematology. https://doi.org/10.1007/s00277-026-07270-z

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07270-z

Keywords: myelodysplastic syndromes, immature platelet fraction, biomarker, prognosis, azacitidine, acute myeloid leukemia, leukemia-free survival, thrombopoiesis, megakaryocytes, hematology, prospective cohort study, Revised International Prognostic Scoring System

The study, led by Tomás José González-López of Hospital Universitario de Burgos and colleagues across 22 Spanish centers, analyzed 72 adults with ITP drawn from a broader national cohort of 174 patients who had received the drug. The median age of participants was 67 years, and 55.6 percent were women, a demographic profile that reflects the typical real-world ITP population far better than the carefully selected patients enrolled in pharmaceutical registration trials. Half of the patients carried at least one comorbidity on the Charlson Comorbidity Index, and roughly a quarter had experienced bleeding in the month before starting fostamatinib, underscoring the clinical urgency that often drives treatment decisions in this disease.

ITP is an acquired immune-mediated disorder in which platelet counts fall because of a double hit: antibodies and cytotoxic T lymphocytes accelerate platelet destruction in the spleen and elsewhere, while defective megakaryocyte maturation impairs the production of replacement platelets in the bone marrow. The clinical course is highly variable. Some patients remain asymptomatic despite platelet counts well below 100 × 10⁹ per liter, while others suffer significant mucocutaneous bleeding or develop chronic, relapsing disease that demands years of therapy. Beyond the bleeding risk itself, ITP carries a substantial burden on quality of life and healthcare resources, particularly for patients who cycle through multiple treatment lines without achieving durable control.

Standard first-line therapy remains corticosteroids, sometimes supplemented by intravenous immunoglobulin when rapid platelet increases are needed. Although initial steroid responses are high, relapse after dose tapering is common, and many patients become corticosteroid-dependent with all the metabolic and infectious complications that entails. Second-line options include thrombopoietin receptor agonists such as eltrombopag and romiplostim, the anti-CD20 antibody rituximab, and splenectomy. Each has drawbacks: TPO receptor agonists require continuous administration and raise concerns about thromboembolic risk in some patients, while rituximab and splenectomy can produce durable remissions but carry delayed onset, variable long-term efficacy, and procedure- or immunosuppression-related hazards. Guidelines therefore emphasize individualized sequencing, and the search for well-tolerated earlier options has intensified.

Fostamatinib attacks the disease from a different angle. As an oral inhibitor of spleen tyrosine kinase, or SYK, it interferes with Fcγ receptor signaling in macrophages, the scavenger cells that phagocytose antibody-coated platelets. By blocking this pathway, the drug reduces antibody-dependent platelet destruction rather than simply stimulating platelet production. Its efficacy and safety were established in the pivotal phase 3 FIT trials in patients with persistent and chronic ITP who had already received multiple prior therapies, leading to regulatory approval for chronic ITP in adults refractory to other treatments. But those trials, by design, tested the drug late in the disease course, leaving a gap in evidence about how it performs when introduced earlier.

The new Spanish study was designed to fill that gap. Patients received fostamatinib at the European Medicines Agency-approved starting dose of 100 milligrams twice daily, with escalation to 150 milligrams twice daily after four weeks if platelet responses were inadequate and tolerability permitted. Fifty-six point nine percent of patients ultimately required the higher dose, typically after a median of 24 days. Forty patients, or 55.5 percent, took fostamatinib as monotherapy throughout their treatment, while the remainder used it alongside tapering corticosteroids, immunoglobulin, or other agents. The median time from ITP diagnosis to fostamatinib initiation was 17 months, and the baseline platelet count stood at just 28 × 10⁹ per liter.

The effectiveness results were striking. Overall, 83.3 percent of patients achieved a response, defined as a platelet count of at least 30 × 10⁹ per liter with at least a twofold increase from baseline, resolution of bleeding, and no rescue therapy within the preceding eight weeks. Complete response, meaning a platelet count of at least 100 × 10⁹ per liter, was reached by 65.3 percent. When fostamatinib was used as second-line therapy, 76.0 percent responded, with 56.0 percent achieving complete response; in the third-line setting, the figures rose to 87.2 percent and 70.2 percent respectively. The median time to platelet response was a brisk 10.5 days, and patients reached their peak platelet counts, a median of 140 × 10⁹ per liter, after a median of 62 days. Across the 42-month observation window, patients spent a cumulative 76.8 percent of their time in response.

Exploratory subgroup analyses hinted at interesting patterns, though the investigators caution that these were hypothesis-generating and based on small numbers. Response rates were higher among women than men, 92.5 versus 71.9 percent, and higher in chronic than in non-chronic ITP by the same margin. Patients previously treated with eltrombopag responded more often than those without such exposure, 96.3 versus 75.6 percent, while prior romiplostim exposure was associated with a lower rate. Notably, second-line use was associated with faster platelet recovery, a median of 32 days to peak count compared with 77 days for third-line use, suggesting that earlier introduction may speed benefit even when overall efficacy is similar. Twenty-seven point eight percent of patients discontinued the drug for insufficient effectiveness, and only four patients, 5.5 percent, managed to stop fostamatinib successfully after responding, indicating that the drug is best regarded as long-term maintenance therapy rather than a finite course.

Safety data were reassuring. Adverse events occurred in 44.4 percent of patients and were predominantly mild to moderate, with diarrhea, hypertension, and headache the most common complaints, generally manageable with symptomatic treatment. Only 15.3 percent of patients stopped the drug because of toxicity, and severe grade 3 to 4 events were infrequent. Three thromboembolic events occurred, two deep vein thromboses and one pulmonary embolism, but all three patients had established thrombotic risk factors unrelated to the drug, including advanced age, obesity, and immobilization. Given growing recognition that ITP itself carries an elevated thrombotic risk, the low incidence observed here, 4.2 percent, may represent a meaningful advantage for patients with cardiovascular comorbidities, a group well represented in this elderly cohort.

The findings align with a growing body of international real-world evidence, including the Spanish FOSTASUR study, the Italian GIMEMA ITP 1122 experience, and a post hoc analysis of the FIT trials that reported response rates of 94 percent and 86 percent for second- and third-line use respectively. The authors acknowledge the limitations inherent to an observational design without a control group, but the consistency across independent cohorts strengthens the case. Their conclusion is direct: fostamatinib should be considered earlier in the ITP treatment algorithm rather than reserved as a last resort, with prospective studies now needed to define the optimal timing and sequencing of a drug that, for many patients, may offer rapid, durable platelet recovery with an acceptable safety profile.

Subject of Research: Real-world effectiveness and safety of early-line fostamatinib therapy in adult immune thrombocytopenia

Article Title: Early Use of Fostamatinib in Immune Thrombocytopenia

Article References: González-López, T. J., Bermejo-Vega, N., Cardesa-Cabrera, R., Acedo, N., Luis-Navarro, J., Lakhwani, S., Bernat, S., Haces-Tirado, G. E., Galán, P., Lozano, M. L., Martínez-Carballeira, D., Hernández-Martin, R., Jimenez-Bárcenas, R., Navas-Elorza, B., Marcellini, S., Torres-Tienza, A., Perona-Blázquez, A., Benet, C., Fernandez-Jimenez, D., … García-Donás Gabaldón, G. (2026). Early Use of Fostamatinib in Immune Thrombocytopenia. Advances in Therapy. https://doi.org/10.1007/s12325-026-03769-z

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03769-z

Keywords: immune thrombocytopenia, fostamatinib, SYK inhibitor, second-line therapy, third-line therapy, platelet response, real-world study, hematology, autoimmune disease, drug safety, thrombosis risk, Spain

The scale of the unmet need is difficult to overstate. Myelodysplastic syndromes are diagnosed in approximately 10,000 to 15,000 people in the United States each year, a figure that experts believe may undercount the true burden because the disease can be difficult to recognize in its early stages. MDS arises when the blood-forming cells in the bone marrow malfunction, producing defective blood cells that crowd out healthy ones. Patients often suffer from anemia, infections, and bleeding complications, and the only potentially curative treatment for most patients, a stem cell transplant, carries substantial risks that many older patients cannot tolerate. Because the disease disproportionately affects people over the age of 65, its prevalence is expected to climb as populations age, making sustained research investment not just desirable but urgent.

What makes the SCOR model distinctive is its insistence on collaboration across institutional and disciplinary boundaries. Rather than funding a single laboratory to pursue a single hypothesis, each SCOR award brings together teams of leading investigators working across institutions and scientific disciplines, supporting multiple interconnected projects under one research program. The design reflects a hard-won lesson in modern biomedical science: complex diseases rarely yield to isolated approaches. A geneticist studying clonal hematopoiesis, an immunologist probing the bone marrow microenvironment, and a clinician testing novel therapeutic combinations may each hold a piece of the puzzle, but the pieces only fit together when the investigators are structurally encouraged to share data, reagents, and ideas. SCOR grants are built to make that integration the default rather than the exception, accelerating scientific discovery and helping move promising research closer to clinical application.

The financial architecture of the program is equally deliberate. Each SCOR award provides up to $5 million over five years, giving research teams the stability and long-term support needed to tackle complex scientific challenges that may take years to solve. In a research funding landscape dominated by short grant cycles of two to three years, five-year commitments allow scientists to pursue questions that require patience: longitudinal studies of disease progression, the development and validation of new disease models, and early-stage therapeutic concepts that are too speculative for conventional funding mechanisms. The program is designed to support collaborative research efforts that can generate new insights and ultimately improve outcomes for patients, a goal that both partner organizations describe as central to their missions.

Lore Gruenbaum, chief scientific officer for Blood Cancer United, framed the collaboration as more than a financial transaction. “MDS remains an area of significant unmet need, and progress depends on both scientific innovation and collaboration,” Gruenbaum said. “This collaboration brings together more than funding. It combines scientific expertise, deep knowledge of the challenges facing patients with MDS, and a shared commitment to accelerating progress. By working together, we can support research with the potential to deepen our understanding of the disease and help drive better outcomes for patients.” Her remarks underscore a strategic shift among major cancer philanthropies toward pooled funding models, in which organizations combine resources to support programs that neither could sustain alone at the same scale.

For the Edward P. Evans Foundation, the partnership represents a continuation of a singular focus. Founded in 1984, the foundation is a non-profit charitable trust dedicated to funding research on myelodysplastic syndromes through its EvansMDS Initiative, whose mission is to fuel the discovery of new knowledge that will lead to better MDS therapies and, ultimately, disease cures. Timothy Graubert, the foundation’s president, emphasized the importance of sustained investment in a disease that has historically attracted less attention and fewer research dollars than more prominent cancers. “We’re committed to supporting innovative, high-impact research that advances our understanding of MDS and moves us closer to better treatments and cures,” Graubert said. “We’re proud to collaborate with Blood Cancer United to support investigators pursuing discoveries that can improve outcomes for patients and families affected by this disease.”

The scientific stakes of this investment are considerable. Over the past two decades, researchers have made striking progress in mapping the genomic landscape of MDS, identifying recurrent mutations in genes that regulate splicing, DNA methylation, and other cellular processes. Yet translating that knowledge into therapies has proved frustratingly slow. Hypomethylating agents remain a mainstay of treatment decades after their introduction, and while newer targeted therapies and a class of drugs called luspatercept have offered meaningful gains for subsets of patients, resistance and relapse remain common. A coordinated, well-funded research program that connects basic discovery with translational science is precisely the kind of infrastructure that could help close the gap between genetic insight and clinical benefit, particularly for patients whose disease transforms into acute myeloid leukemia, an event that dramatically worsens prognosis.

The MDS-focused award is one of two SCOR funding opportunities currently accepting proposals, together representing up to $10 million in potential multi-year research investments focused on areas of significant unmet need across all blood cancers. The second award, funded solely by Blood Cancer United, will prioritize research into another area of high unmet need, such as T-cell lymphoma, myeloproliferative neoplasms, high-risk multiple myeloma, or childhood leukemia. These are diseases that, for different reasons, have resisted the therapeutic advances seen in other parts of oncology. T-cell lymphomas are rare and biologically heterogeneous, making clinical trials difficult to design and enroll. Myeloproliferative neoplasms, though often manageable for years, still lack treatments that fundamentally alter disease course. High-risk multiple myeloma and childhood leukemia each present distinct scientific and clinical challenges that demand sustained focus rather than episodic attention.

Blood Cancer United’s decision to concentrate resources on these persistent gaps reflects a broader philosophy about how philanthropy can best serve patients. The organization, which has been serving people with blood cancer since its founding in 1949, has invested more than $2 billion in clinical research over its history, funding that has contributed to dramatic improvements in survival rates across leukemia, lymphoma, myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms. Yet the organization’s leadership has been explicit that diseases affecting smaller patient populations require deliberate, sustained scientific focus, because market forces alone rarely incentivize the depth of research needed to transform outcomes for rare and underserved communities. By pairing its own resources with those of a foundation devoted exclusively to MDS, Blood Cancer United is betting that shared commitment, combined expertise, and patient-centered priorities can accomplish what fragmented, short-term funding cannot.

For the patients and families affected by myelodysplastic syndromes, the announcement carries a message that extends beyond the dollar figures. It signals that two major research funders view MDS as a solvable problem, one worth a five-year, deeply collaborative scientific campaign. Investigators interested in the SCOR program can find details about the funding opportunities through Blood Cancer United, and proposals are now being accepted for both the MDS-focused award and the second SCOR award covering other high-need areas. Whether this investment yields new therapeutic targets, better disease models, or improved ways to predict which patients will progress to leukemia, its most immediate effect may be cultural: a demonstration that in the fight against blood cancers, collaboration across institutions, disciplines, and organizations is not merely an ideal but a funded, operational strategy for accelerating discovery toward cures.

Subject of Research: A collaborative $5 million SCOR research grant to advance myelodysplastic syndromes research

Article Title: Blood Cancer United and Edward P. Evans Foundation collaboration advances research for patients with myelodysplastic syndromes

Article References: Blood Cancer United and Edward P. Evans Foundation collaboration advances research for patients with myelodysplastic syndromes. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: myelodysplastic syndromes, MDS, Blood Cancer United, Edward P. Evans Foundation, SCOR grant, blood cancer research, acute myeloid leukemia, research funding, hematology, collaborative science, T-cell lymphoma, myeloproliferative neoplasms

The argument builds on a striking real-world study that has recently energized the field. A retrospective, two-stage cohort analysis by Chen and colleagues examined early bone-marrow-guided venetoclax management in patients with newly diagnosed acute myeloid leukemia who were considered unsuitable for intensive chemotherapy. Among 371 evaluable patients, the investigators found that using early marrow assessments to guide treatment was associated with significantly reduced early venetoclax exposure and a marked drop in day-56 infection-related hospitalization, which fell from 37.4 percent to 24.0 percent, corresponding to an adjusted odds ratio of 0.46 with a p-value of 0.005. In other words, simply looking at the marrow earlier allowed clinicians to pull back on the drug before the most dangerous toxicities took hold.

The second stage of the Chen study sharpened the finding further. Among 237 patients who responded to initial therapy, shortening venetoclax to fourteen days or fewer per cycle reduced prolonged grade-4 neutropenia from 61.0 percent to 41.6 percent, an adjusted odds ratio of 0.41 with a p-value of 0.003. Infection-related hospitalization also fell, with an adjusted odds ratio of 0.43 and a p-value of 0.014. Critically, these toxicity reductions came without any significant change in measurable residual disease negativity, overall survival, or relapse-free survival. For a drug whose most feared side effect is profound, prolonged neutropenia that opens the door to life-threatening infections, the implication is provocative: some patients may be receiving more venetoclax than they need, and the excess exposure may be pure harm.

Yet the editorial is careful to frame these results as a beginning rather than an endpoint. Because the Chen study was retrospective, its findings are vulnerable to selection bias; clinicians may have shortened therapy preferentially in patients who already looked healthier, which could inflate the apparent safety benefit. The absence of randomization means the two compared groups may have differed in ways the statistical adjustments could not fully capture. Adnan also notes that the study showed no significant difference in overall survival or progression-free survival, which supports the idea that shortening was not harmful but does not prove that shortened venetoclax is truly equivalent in efficacy. Prospective, ideally randomized validation remains the essential next step before practice changes on a wide scale.

There is a deeper conceptual problem as well, and it sits at the heart of the proposed framework. Bone marrow morphology, the century-old practice of examining stained marrow smears under a microscope, is functional and widely available, but it is a blunt instrument. It can miss small populations of leukemic cells that persist below the threshold of visual detection, and its interpretation varies between observers. The editorial contends that early marrow morphology is useful but insufficient on its own, and that relying on a single marker to decide whether to curtail a backbone therapy in a disease as heterogeneous as acute myeloid leukemia is inherently risky.

This is where measurable residual disease enters the picture. A consensus document from the European LeukemiaNet MRD Working Party, authored by Heuser and colleagues, established MRD as a central biomarker in acute myeloid leukemia, serving prognostic, predictive, monitoring, and efficacy-response functions. A positive or negative MRD result indicates whether quantifiable disease is detected above specific thresholds, but those thresholds differ depending on the assay and the laboratory performing it. Flow cytometry, polymerase chain reaction-based assays for mutations such as NPM1, and other techniques each carry distinct sensitivities and limitations, which means an MRD result must always be interpreted in context rather than treated as an absolute verdict.

Recognizing these limitations, recent work by Bancos and colleagues has advocated a multimodal approach to residual disease assessment, tracing the evolution from cytogenetics and molecular biology to emerging technologies such as methylation pattern analysis and surface-enhanced Raman scattering. Each molecular marker, whether marrow morphology, conventional MRD, or molecular MRD via next-generation sequencing, may contribute to diagnosis and monitoring, but none is individually sufficient to guide every treatment decision. The editorial takes this logic one step further and applies it specifically to the question of venetoclax duration, proposing that the integration of multiple markers could provide a more precise and personalized basis for deciding when to stop or shorten therapy.

The framework also draws inspiration from the broader multi-omics movement in hematology. A review by Soleimani Samarkhazan highlighted how integrating complementary molecular and transcriptomic indicators can enable more accurate response-adapted approaches in acute myeloid leukemia, potentially allowing venetoclax duration to be customized according to both morphological and biological measures of disease response. Under such a model, a patient whose marrow clears rapidly, whose MRD assays turn negative early, whose leukemic clone shows molecular responses on sequencing, and whose blood counts recover promptly might safely de-escalate to shorter venetoclax cycles. Conversely, a patient with persistent molecular evidence of disease might continue full-dose therapy or be considered for escalation, even if the microscope looks reassuringly empty.

The stakes of getting this right are considerable. Acute myeloid leukemia is a progressively increasing form of leukemia with consistently high incidence and mortality, imposing a growing strain on health systems worldwide. Projections based on the Global Burden of Disease Study 2021 estimate that by 2040 the number of cases will rise significantly, with predicted figures reaching approximately 184,287.88 for incidence and 165,537.59 for mortality. The economic toll is equally sobering: a United States analysis by Hagiwara and colleagues of 9,455 newly diagnosed patients found that the average healthcare cost per patient was 386,077 dollars. Every day of unnecessary venetoclax exposure adds hospitalizations, growth factor use, transfusions, and infection management to that bill, while every day of insufficient exposure risks relapse, which is far more expensive and far more deadly.

What makes the editorial’s proposal compelling is that it reframes a question the field has been circling for years. Venetoclax-based regimens have delivered unprecedented response rates in unfit patients, but the drug’s hallmark toxicity, myelosuppression, has remained a stubborn constraint, and clinicians have lacked a principled way to know when enough is enough. By proposing a multi-marker panel that unites marrow morphology, MRD, molecular MRD via next-generation sequencing, and hematologic recovery, the editorial sketches a route toward treating venetoclax duration the way modern oncology treats nearly everything else: as a variable to be tuned by data rather than fixed by tradition. The author acknowledges the constraints of the underlying evidence, including the retrospective design of the pivotal real-world study and the possibility that no single marker can capture the full complexity of the disease. But the direction of travel is clear, and the call for prospective research into a multi-marker response-adapted framework gives the field a concrete hypothesis to test. If randomized studies confirm that response-guided shortening preserves survival while stripping away toxicity, the fixed ten-plus-month venetoclax paradigm could give way to something smarter, safer, and genuinely personal, and the editorial argues that the tools to build that future are already on the laboratory bench.

Subject of Research: Response-adapted venetoclax dosing guided by multi-marker disease assessment in acute myeloid leukemia

Article Title: Presenting a multi-marker response-adapted framework for venetoclax duration in acute myeloid leukemia

Article References: Adnan, N. (2026). Presenting a multi-marker response-adapted framework for venetoclax duration in acute myeloid leukemia. Annals of Hematology, 105(10), Article 414. https://doi.org/10.1007/s00277-026-07280-x

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07280-x

Keywords: acute myeloid leukemia, venetoclax, measurable residual disease, bone marrow morphology, next-generation sequencing, BCL-2 inhibitor, neutropenia, response-adapted therapy, multi-omics, hematology, treatment de-escalation, European LeukemiaNet

Waldenström macroglobulinemia is a rare and indolent B-cell lymphoma characterized by the accumulation of malignant lymphoplasmacytic cells in the bone marrow and, crucially, by the overproduction of monoclonal immunoglobulin M, an antibody protein that thickens the blood and can cause hyperviscosity, neuropathy, and organ damage. Because the disease is uncommon, most treatment evidence comes from small trials and single-arm studies, leaving clinicians with genuine uncertainty when patients relapse after frontline therapy. This rarity is precisely why the French group’s multicenter approach matters: by pooling patients from 17 centers, the investigators assembled one of the larger cohorts ever reported for this specific treatment strategy.

The drug at the center of the study, venetoclax, belongs to a class of agents known as BH3 mimetics. These small molecules bind to BCL-2, an anti-apoptotic protein that many B-cell cancers exploit to evade programmed cell death. By occupying the BCL-2 binding groove, venetoclax releases the cellular brakes on apoptosis, allowing malignant lymphocytes to self-destruct. The drug has already transformed the treatment landscape for chronic lymphocytic leukemia, and earlier monotherapy studies suggested promising activity in relapsed or refractory Waldenström macroglobulinemia, a population with significant unmet medical need. What remained unclear was whether venetoclax should be given alone or in combination with other agents in this disease.

The WAVE investigators turned to real-world clinical practice to answer that question. The 46 patients included in the analysis had received a median of three prior lines of treatment before starting venetoclax, and 89 percent had already been exposed to a Bruton tyrosine kinase inhibitor, the class of drugs that has become a cornerstone of Waldenström macroglobulinemia therapy. This detail is important: these were heavily pretreated patients whose disease had already evaded the most effective modern targeted therapies, meaning that any meaningful response signal carries real clinical weight. Among the cohort, 25 patients, or 54 percent, received venetoclax combined with an anti-CD20 antibody, typically rituximab or a related monoclonal antibody that targets the CD20 surface protein found on B cells and recruits the immune system to destroy antibody-coated tumor cells.

The headline finding concerns response depth. At the time of best response, patients treated with the combination achieved a deep response rate, defined as very good partial response plus uncertain complete response, of 56 percent, compared with just 24 percent among those treated with venetoclax monotherapy, a difference that reached statistical significance with a p value of 0.03. In lymphoma care, depth of response is not an academic nicety. Deeper remissions, particularly those in which the monoclonal IgM protein falls to very low or undetectable levels, are consistently associated with longer periods of disease control before relapse. For a disease in which the abnormal protein itself drives many of the symptoms, pushing IgM down as far as possible translates directly into clinical benefit.

Perhaps more striking was the result of the multivariate analysis. When the investigators adjusted for other clinical variables, anti-CD20 combination therapy emerged as the only factor independently associated with achieving a deep response, with a hazard ratio of 4.07 and a p value of 0.03. In other words, the antibody combination quadrupled the odds of a deep remission regardless of other patient characteristics. This kind of signal, emerging from a retrospective dataset where treatment assignment was not randomized, cannot prove causation on its own, but it provides a strong rationale for the prospective trials that the authors say are needed to confirm the strategy.

The progression-free survival data reinforced the same direction of benefit, though with more statistical uncertainty. At two years, 78 percent of patients treated with venetoclax plus anti-CD20 had not experienced disease progression or death, compared with 54 percent of those on monotherapy. The confidence intervals were wide, spanning 54 to 90 percent for the combination arm and 27 to 74 percent for monotherapy, and the difference did not reach statistical significance with a p value of 0.25. That lack of formal significance is unsurprising given the modest sample size, but the magnitude of the gap, nearly 25 percentage points at two years, is the kind of signal that clinicians and trial designers take seriously.

Safety, as always in combination therapy, is the counterweight to efficacy, and here the picture was more nuanced. Grade 3 or higher adverse events occurred in 17 patients, or 68 percent, of those receiving the combination, versus 7 patients, or 33 percent, of those on venetoclax alone, a difference that was statistically significant with a p value of 0.02. Three cases of febrile aplasia, episodes of fever accompanied by severe suppression of blood cell production, were reported, though these did not differ significantly between the two groups. The increased toxicity of the combination is consistent with what is known about adding antibody therapy to targeted agents: the pairing amplifies immune-mediated tumor killing but also increases the burden on the bone marrow and the immune system. For a largely elderly patient population, this trade-off between deeper remissions and higher rates of serious side effects will need careful weighing in future prospective studies.

The WAVE study also illustrates a broader shift in how rare-cancer evidence is generated. Randomized trials in diseases with incidence rates as low as Waldenström macroglobulinemia’s can take years to accrue even modest numbers of patients, and many relapsed patients cannot wait. Retrospective multicenter cohorts like this one, harmonized across 17 institutions and analyzed with multivariate statistics, offer a pragmatic middle path: they capture the messy reality of clinical practice, including heterogeneous prior treatments and variable dosing schedules, and they generate hypothesis-driving signals that can justify the prospective studies that ultimately change guidelines. The French FILO network has been particularly productive in this regard, leveraging the centralized structure of French hematology care to assemble cohorts that individual centers never could.

For patients and their physicians, the practical message is cautiously encouraging. Venetoclax, with or without an anti-CD20 antibody, is an oral, targeted, chemotherapy-free approach for a disease that has historically been treated with rituximab-based chemoimmunotherapy, proteasome inhibitors, or BTK inhibitors. The WAVE data suggest that in the relapsed or refractory setting, particularly after BTK inhibitor exposure, the combination strategy offers the best chance of a deep and durable response, at the cost of more frequent severe side effects. The authors themselves frame the findings as warranting further evaluation in prospective studies, and that is the appropriate note of restraint. Until randomized data arrive, the study gives hematologists a real-world benchmark and gives patients with few remaining options a reason for measured optimism that the next generation of trials will refine exactly who benefits most from this two-pronged attack on their cancer.

Subject of Research: Venetoclax with or without anti-CD20 antibody therapy for relapsed or refractory Waldenström macroglobulinemia

Article Title: Relapsed/refractory WAldenström macroglobulinemia patients treated by VEnetoclax with or without anti-CD20 antibody: WAVE a retrospective study of the French CLL/WM group (FILO)

Article References: Vonfeld, M., Systchenko, T., Debureaux, P.-E., Dupuis, J., Roos-Weil, D., Ysebaert, L., Dilhuydy, M.-S., Malphettes, M., Croizier, C., Aurran, T., Inchiappa, L., Willems, L., Hivert, B., Lévy, V., Bussot, L., Bouclet, F., Laribi, K., Clavert, A., Durand, A., & Tomowiak, C. (2026). Relapsed/refractory WAldenström macroglobulinemia patients treated by VEnetoclax with or without anti-CD20 antibody: WAVE a retrospective study of the French CLL/WM group (FILO). Annals of Hematology. https://doi.org/10.1007/s00277-026-07293-6

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07293-6

Keywords: Waldenström macroglobulinemia, venetoclax, anti-CD20 antibody, BTK inhibitor, relapsed refractory lymphoma, BCL-2, targeted therapy, retrospective study, hematology, monoclonal antibody, progression-free survival, FILO

Situs inversus totalis is a congenital condition in which the major visceral organs are reversed from their normal positions along the left-right axis. The liver comes to lie predominantly on the left, the stomach and spleen shift to the right, and the cardiac apex points rightward, a configuration called dextrocardia. Estimates of its prevalence vary, but the condition is generally thought to affect roughly one in ten thousand individuals, and many carriers live their entire lives unaware of their mirrored anatomy. The condition arises during embryogenesis, when the normally stereotyped left-right patterning of the developing embryo is globally reversed. A landmark study by Nonaka and colleagues, published in Nature in 2002 and cited in the report’s reference list, demonstrated in the mouse embryo that the directional flow of fluid across the node, the embryonic organizer structure, is sufficient to determine left-right patterning, and that artificially reversing this flow reverses organ situs. Motile cilia at the node generate this leftward current, and defects in ciliary function underlie many cases of laterality disorders, including both situs inversus and the more chaotic arrangement known as heterotaxy.

As Sutherland and Ware summarized in their 2009 review of disorders of left-right asymmetry, the clinical significance of situs anomalies lies less in the mirroring itself than in its associations. Pure situs inversus totalis, in which the reversal is complete and orderly, is frequently an incidental finding discovered on imaging performed for unrelated complaints. Heterotaxy, by contrast, involves ambiguous or discordant organ positioning and is strongly associated with congenital heart disease and other malformations. A hospital-based study by Chen and colleagues published in Birth Defects Research in 2020 examined comorbidities in patients with situs inversus totalis and documented the range of conditions that accompany the mirrored anatomy in hospital populations. Clinicians must also contend with the practical consequences of reversed anatomy: physical examination findings are transposed, electrocardiograms require lead reversal for correct interpretation, appendicitis presents with left-sided pain, and surgical approaches must be rethought from first principles.

Into this already unfamiliar anatomical landscape, the Japanese team’s patient added a second layer of complexity. The case involves a patient found to have massive splenomegaly, an abnormal enlargement of the spleen, in the setting of malignant lymphoma, a cancer of the lymphatic system. The keywords attached to the published article situs inversus, malignant lymphoma, and splenomegaly capture the three threads of the story. In a body with normal organ arrangement, an enlarged spleen occupies the left upper quadrant of the abdomen and can be identified by its characteristic shape, its relationship to the ribs and stomach, and its homogeneous tissue density on computed tomography or ultrasound. In a patient with situs inversus totalis, the spleen resides on the right, and when it grows to enormous size it can extend across the midline, displace neighboring structures, and present an imaging appearance that mimics other organs.

The central image that gives the report its title shows a spleen so enlarged and so altered in texture that it resembled liver parenchyma. The phrase liver-like spleen refers to this visual deception: on cross-sectional imaging, the organ’s density and architecture appeared more like hepatic tissue than like the typical spleen. For clinicians evaluating a patient with reversed anatomy and a large right-sided or midline abdominal mass, distinguishing an enormously enlarged spleen from a displaced or accessory liver lobe, a tumor, or an abnormal collection of fluid is not a trivial exercise. The authors’ acknowledgment section thanks Dr. Ken Sadahira and Dr. Mikio Okayama for their assistance in patient care, indicating that the case was managed by a clinical team rather than observed from afar. The report also notes that no datasets were generated or analyzed, consistent with its format as a clinical image publication rather than a research study.

The association between lymphoma and the spleen is well established. The spleen is a lymphoid organ, and lymphomas, which arise from lymphocytes, frequently involve it. Splenomegaly in lymphoma may reflect direct infiltration by malignant cells, congestion, or reactive changes, and an enlarged spleen can itself be the presenting sign that brings a patient to medical attention. Trautner and colleagues, in a 2010 report in Clinical Nuclear Medicine cited by the Japanese authors, described the additional value of hybrid imaging in a patient with newly diagnosed lymphoma who also happened to have situs inversus totalis, underscoring that this combination of mirrored anatomy and hematologic malignancy, while rare, recurs often enough in the literature to merit attention. When the two coincide, the diagnostic radiologist must interpret every image against a reversed anatomical template, and subtle findings can be misassigned to the wrong organ.

Eitler, Bibok, and Telkes, writing in the International Journal of General Medicine in 2022, provided a clinical review of situs inversus totalis that frames the practical stakes. They emphasized that while most affected individuals are asymptomatic, the condition demands vigilance in diagnostic reasoning, surgical planning, and the interpretation of imaging studies. Their review, together with the earlier genetic and epidemiological work cited in the present case report, forms the scholarly backdrop against which the Kawasaki team’s images should be read. The report’s contribution is not a new therapy or a genetic discovery but a vivid demonstration of how far normal anatomical assumptions can mislead even experienced clinicians when the underlying blueprint is mirrored and then distorted by disease.

The publication process itself reflects the case’s timeline. According to the article’s record, the manuscript was received on 1 April 2026, accepted on 24 September 2026, and published on 1 October 2026 in the Journal of General Internal Medicine, the flagship journal of the Society of General Internal Medicine. All three authors are affiliated with Kawasaki Municipal Kawasaki Hospital in Kanagawa, Japan, with Okamoto based in the Department of Hematology and Miyaki and Kamiya in the Department of Internal Medicine, Kamiya holding appointments in both departments. Miyaki wrote the initial draft of the manuscript, and all authors had access to the data and helped revise the intellectual content. The authors declared no conflicts of interest and received no funding for the work. Correspondence for the article is directed to Takahiro Kamiya, whose ORCID identifier is listed in the publication record.

Why should a single clinical image merit attention beyond the ward? The answer lies in the pedagogical power of the exceptional case. Medical education proceeds in part through pattern recognition, and patterns are learned from typical presentations. But diagnostic error frequently occurs at the boundaries, where rare anatomy, rare disease, and rare combinations interact. A liver-like spleen in a patient with situs inversus totalis is precisely such a boundary case. It reminds radiologists that organ identification rests on more than position and density, that clinical history and correlative imaging are indispensable, and that the mirrored body can transform familiar signs into unfamiliar configurations. For internists and hematologists, it reinforces the point that splenomegaly in lymphoma can reach sizes and textures that confound standard heuristics.

The case also connects to one of the most elegant stories in developmental biology. The discovery that cilia-driven nodal flow sets the left-right axis, confirmed by the artificial flow experiments in mice, transformed laterality disorders from a descriptive curiosity into a mechanistically understood class of conditions. Every patient with situs inversus totalis carries in their anatomy the fossil record of that embryological decision, reversed at its origin. When disease such as lymphoma then remodels the reversed organs, clinicians are asked to read two overlapping stories at once: the congenital mirror and the acquired pathology. The image published by Miyaki, Okamoto, and Kamiya captures that intersection in a single frame, a spleen grown so large and altered that it borrowed the appearance of its mirrored neighbor, the liver. For the general reader, it is a striking reminder that human anatomy, even at its most orderly, holds surprises, and that medicine’s textbooks are at best maps of the average, to be consulted with humility whenever an individual patient departs from it.

Subject of Research: Splenomegaly resembling liver tissue in a patient with situs inversus totalis and malignant lymphoma

Article Title: A Liver-like Spleen in Situs Inversus Totalis

Article References: Miyaki, Y., Okamoto, S., & Kamiya, T. (2026). A Liver-like Spleen in Situs Inversus Totalis. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10873-x

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10873-x

Keywords: situs inversus, splenomegaly, malignant lymphoma, clinical imaging, left-right asymmetry, dextrocardia, heterotaxy, nodal cilia, hematology, diagnostic radiology, congenital anatomy, case report